Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: Clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors

Tumori

Volumn 97, Issue 5, 2011, Pages 620-628

  Sclafani, Francesco ^a   Carnaghi, Carlo ^a   Di Tommaso, Luca ^a   Rodari, Marcello ^a   Destro, Annarita ^a   Rimassa, Lorenza ^a   Giordano, Laura ^a   Chiti, Arturo ^a   Roncalli, Massimo ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Immunohistochemistry; Neuroendocrine tumors; Somatostatin receptor scintigraphy; Somatostatin receptors

Indexed keywords

HYDRAZINONICOTINYL OCTREOTIDE[3 TYROSINE] TC 99M; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CARCINOID; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM TUMOR; FEMALE; FOREGUT CARCINOID; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HINDGUT CARCINOID; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDGUT CARCINOID; NEUROENDOCRINE TUMOR; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCINTIGRAPHY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; WHOLE BODY PET;

EID: 83055193670     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700514     Document Type: Article

References (29)

1. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci, 89: 251-255, 1992.
2. Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell GI, Seino S: Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol, 6: 2136-2142, 1992. (Pubitemid 23021563)
3. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S, Seino Y: Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun, 195: 844-852, 1993. (Pubitemid 23280493)
4. Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, Schindler M, Cole S, Bussolati G: Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. Virchows Arch, 440: 461-475, 2002.
5. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y: Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest, 93: 1321-1325, 1994. (Pubitemid 24087192)
6. Janson ET, Gobl A, Kälkner KM, Oberg K: A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res, 56: 2561-2565, 1996.
7. Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K: Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res, 58: 2375-2378, 1998. (Pubitemid 28252697)
8. John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherübl H, Boese-Landgraf J, Neuhaus P, Ziske C, Mölling K, Riecken EO, Reubi JC, Wiedenmann B: Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut, 38: 33-39, 1996. (Pubitemid 26020927)
9. Lamberts SWJ, Krenning EP, Reubi JC: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev, 12: 450-482, 1991.
10. 111In-DTPA-DPhe1] octreotide in somatostatin receptor-positive organs. J Nucl Med, 44: 1315-1321, 2003.
11. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol, 15: 966-973, 2004. (Pubitemid 39004355)
12. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ: Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol, 46: 723-734, 2007. (Pubitemid 47123757)
13. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med, 27: 273-282, 2000. (Pubitemid 30167697)
14. 111In-DTPA-D-Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocr, 131: 577-581, 1994.
15. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E: Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med, 44: 42-49, 2000. (Pubitemid 30325952)
16. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, le Guludec D: Clinical impact of somatostatin receptor scintigraphy in themanagement of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med, 38: 853-858, 1997. (Pubitemid 27251972)
17. Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, Arnold R: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut, 50: 52-60, 2002. (Pubitemid 34028303)
18. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L: Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol, 26: 963-970, 2008. (Pubitemid 351398091)
19. Lamberts SWJ, Reubi JC, Krenning EP: Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin Oncol, 21 (Suppl 13): 1-5, 1994. (Pubitemid 24378898)
20. Krenning EP, Kwekkeboom DJ, de Jong M, Visser TJ, Reubi JC, Bakker WH, Kooij PP, Lamberts SW: Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide. Semin Oncol, 21 (Suppl 13): 6-14, 1994. (Pubitemid 24378899)
21. 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med, 44: 708-716, 2003.
22. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M: Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol, 20: 1172-1182, 2007. (Pubitemid 47609066)
23. nd edition, pp 61-68, Springer Verlag, Berlin, 2000.
24. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M: Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res, 5: 3483-3487, 1999.
25. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A: Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol, 153: 233-245, 1998. (Pubitemid 28317526)
26. Schulz S, Helmholz T, Schmitt J, Franke K, Otto HJ, Weise W: True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5. Breast Cancer Res Treat, 72: 221-226, 2002. (Pubitemid 34430003)
27. Papotti M, Croce S, Bellò M, Bongiovanni M, Allìa E, Schindler M, Bussolati G: Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours.Virchows Arch, 439: 787-797, 2001.
28. Hofland LJ, Lamberts SWJ: The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev, 24: 28-47, 2003. (Pubitemid 36223278)
29. Hillman N, Herranz L, Alvarez C, Martìnez Olmos MA, Màrco A, Gòmez-Pan A: Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes, 106: 226-230, 1998. (Pubitemid 28356615)